---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-135328"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:50:34.622092+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RxSight prices $100M public stock offering at $56/share for commercial expansion

## Summary
- Offering of 1,785,714 shares at $56/share; underwriters have 30-day option for 267,857 additional shares.
- Net proceeds expected ~$93.2M after underwriting discount and estimated offering expenses.
- Proceeds to fund commercial/marketing expansion (including international), product development, R&D, and working capital.
- Offering expected to close May 13, 2024, subject to customary closing conditions.
- Directors and executive officers subject to 60-day lock-up restrictions on their shares.

## SEC filing metadata
- accession: 0001193125-24-135328
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000119312524135328/0001193125-24-135328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000119312524135328/d832746d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-135328
- JSON: https://secwatch.observer/filing/0001193125-24-135328.json
- Plain text: https://secwatch.observer/filing/0001193125-24-135328.txt

## Key facts
- Material Agreements
  RxSight, Inc. entered into Underwriting Agreement with BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the "Underwriters") valued at approximately $93.2 million (effective 2024-05-08).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the "Underwriters")
  - Value: approximately $93.2 million
  - Effective: 2024-05-08
  source text: On May 8, 2024, RxSight, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell 1,785,714 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1111485/000119312524135328/0001193125-24-135328-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.